Liberty Formula One Grの空売り状況は、投資家がLiberty Formula One Grの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Liberty Formula One Gr (NASDAQ:FWONK) 株価情報, 空売り情報

Liberty Formula One Gr

Liberty Formula One Group

Formula One Group controls the exclusive commercial and promotional rights to the FIA Formula One World Championship series, and the monetization of those rights is the primary business of the group. The firm is responsible for development and promotion of the Formula One race series in concert with its three partners: the FIA (the regulatory body), the teams that participate in the series, and the series' commercial partners, which include the race promoters, broadcasters, sponsors, and advertisers. The F1 schedule in 2023 will encompass 23 races held on five continents. Formula One Group is a subsidiary of Liberty Media, which purchased the firm in January 2017. Formula One stock is a tracking stock for the assets under Formula One Group with Liberty Media.

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.11 by 72.73 percent. This is a 160 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $188.31 million which beat the analyst consensus estimate of $183.00 million by 2.90 percent. This is a 16.58 percent increase over sales of $161.53 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Marcus Q4 2024 GAAP EPS $0.03 Misses $0.11 Estimate, Sales $188.31M Beat $183.00M Estimate

Rosenblatt analyst Steven Frankel maintains Xperi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NYSE">XPER</a>) with a Buy and maintains $15 price target.

Price Target

Analyst Ratings

XPER

Rosenblatt Maintains Buy on Xperi, Maintains $15 Price Target

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.03) by 166.67 percent. This is a 128.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $40.78 million which beat the analyst consensus estimate of $37.37 million by 9.14 percent. This is a 19.13 percent increase over sales of $34.23 million the same period last year.

HRTX

Heron Therapeutics Q4 2024 GAAP EPS $0.02 Beats $(0.03) Estimate, Sales $40.78M Beat $37.37M Estimate

Guidance

TGNA

TEGNA Sees Q1 Revenue Decline Of (-4%) - (-7%)

Baird analyst Jeff Johnson maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral and lowers the price target from $37 to $33.

TNDM

Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $33

TEGNA Sees FY25 Free Cash Flow Of $900M - $1.1B; Capital Expenditure Of $50M - $60M

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Outperform and raises the price target from $50 to $55.

MIRM

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $55

The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi&nbsp;(CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).
 &nbsp;

MDCX

Medicus Pharma Submits Clinical Design (SKNJCT-004) To UAE DOH To Non-Invasively Treat BCC Of The Skin

Rosenblatt analyst Blair Abernethy maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and maintains $660 price target.

SNPS

Rosenblatt Maintains Buy on Synopsys, Maintains $660 Price Target

Baird analyst Joel Beatty maintains Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) with a Neutral and lowers the price target from $10 to $8.

COGT

Baird Maintains Neutral on Cogent Biosciences, Lowers Price Target to $8

Health Care

Stock Split

General

VERO

Venus Concept Will Effect A 1-for-11 Reverse Stock Split, Effective At 5:00 P.M. Eastern Standard Time On March 3

Needham analyst David Saxon reiterates ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) with a Buy and maintains $23 price target.

Reiteration

ZIMV

Needham Reiterates Buy on ZimVie, Maintains $23 Price Target

Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.99) by 11.11 percent. This is a 19.27 percent increase over losses of $(1.09) per share from the same period last year.

Dyne Therapeutics Q4 2024 GAAP EPS $(0.88) Beats $(0.99) Estimate

Baird analyst Jeff Johnson maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $104 to $108.

Baird Maintains Outperform on Alcon, Raises Price Target to $108

Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) reported quarterly earnings of $0.49 per share which missed the analyst consensus estimate of $0.56 by 12.5 percent. This is a 2.08 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $180.43 million which missed the analyst consensus estimate of $183.90 million by 1.88 percent. This is a 0.46 percent increase over sales of $179.61 million the same period last year.

CARS

CORRECTION: Cars.com Q4 Adj EPS $0.49 Misses $0.56 Estimate, Sales $180.43M Miss $183.90M Estimate

Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.16 by 4.31 percent. This is a 181.4 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $870.53 million which missed the analyst consensus estimate of $870.79 million by 0.03 percent. This is a 19.93 percent increase over sales of $725.85 million the same period last year.

Tegna Q4 Adj $1.21 Beats $1.16 Estimate, Sales $870.53M Miss $870.79M Estimate

Rosenblatt analyst Blair Abernethy maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and maintains $205 price target.

SNOW

Rosenblatt Maintains Buy on Snowflake, Maintains $205 Price Target

Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) with a Outperform and raises the price target from $14 to $16.

AHCO

Baird Maintains Outperform on AdaptHealth, Raises Price Target to $16

THRY

Thryv Sees Q1 SaaS Revenue Of $107.5M - $110.0M; SaaS Adjusted EBITDA Of $9.0M - $9.5M

Baird analyst Catherine Schulte maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Outperform and lowers the price target from $161 to $159.

Baird Maintains Outperform on Agilent Technologies, Lowers Price Target to $159

Press Releases

Liberty Media Corporation Announces Annual Investor Meeting

Liberty Media Corporation Reports Third Quarter 2024 Financial Results

Liberty Media Corporation Announces Plan to Split Off Liberty Live Group

Greg Maffei to Step Down as Liberty Media CEO at Year-End in Conjunction with Transactions to Simplify Corporate Structure

Liberty Media Appoints Chase Carey to Board of Directors

Liberty Media Names Robert R. Bennett as Vice Chairman of Board of Directors

Liberty Media Statement on European Commission Decision to Open Phase II Investigation of Proposed Acquisition of MotoGP™

Liberty Media Names Derek Chang as President & Chief Executive Officer

Liberty Media Corporation Announces Fourth Quarter Earnings Release and Conference Call

Liberty Media Corporation Announces 2025 Virtual Annual Meeting of Stockholders

FWONA

FWONK

LLYVA

LLYVK

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Enter Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

Walt Disney

Endeavor Group Holdings, Inc. Class A Common Stock

Endeavor Gr Hldgs

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series A

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

Lions Gate Entertainment Corporation Class A Voting Shares

Lions Gate Entertainment Corporation Class B Non-Voting Shares

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Marcus

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

Liberty Formula One Gr

空売り

Liberty Formula One Gr (NASDAQ:FWONK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル